









市场行情
/
股票
/
nasdaq-urgn
/

Urogen Pharma Ltd

URGN

23.760USD

+0.360+1.54%

收盘 12/24, 13:00（美东）报价延迟15分钟

1.11B总市值

亏损市盈率 TTM



Urogen Pharma Ltd

23.760

+0.360+1.54%

概览公司财务分析

概览

公司

财务

分析

关于 Urogen Pharma Ltd 公司

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Urogen Pharma Ltd简介



公司代码URGN

公司名称Urogen Pharma Ltd

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

员工数量235

证券类型Ordinary Share

年结日May 04

公司地址9 Ha'ta'asiya St

城市RA'ANANA

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Israel

邮编4365007

电话97297707601

网址https://www.urogen.com/

公司代码URGN

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

Urogen Pharma Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

Ms. Cynthia M. Butitta

Independent Director

2.00K

Mr. James A. Robinson, Jr.

Independent Director

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

Dr. Leana S. Wen, M.D.

Independent Director

Mr. Vincent Perrone

Investor Relations

Mr. Daniel G. Wildman

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

Ms. Cynthia M. Butitta

Independent Director

2.00K

Mr. James A. Robinson, Jr.

Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

业务USD

名称

营收

占比

Jelmyto

24.21M

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Jelmyto

24.21M

0.00%

股东统计

更新时间: 12月2日周二

持股股东

股东类型

持股股东

占比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

持股股东

占比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

股东类型

持股股东

占比

Hedge Fund

29.47%

Research Firm

22.98%

Investment Advisor

19.96%

Investment Advisor/Hedge Fund

19.58%

Insurance Company

4.14%

Venture Capital

3.24%

Individual Investor

2.07%

Corporation

1.79%

Private Equity

1.47%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

311

45.66M

97.55%

-6.58M

2025Q2

285

53.00M

114.72%

+5.27M

2025Q1

290

49.25M

108.64%

+1.67M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

2023Q2

222

19.52M

83.40%

-392.05K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RTW Investments L.P.

4.54M

9.82%

+709.10K

+18.49%

Jun 30, 2025

Paradigm BioCapital Advisors LP

2.33M

5.04%

+2.33M

Aug 05, 2025

TD Securities, Inc.

3.19M

6.9%

+1.44M

+82.40%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.47M

3.19%

+1.27M

+633.13%

Jun 30, 2025

Jefferies LLC

2.20M

4.75%

+1.38M

+169.90%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.11M

4.56%

-34.56K

-1.61%

Jun 30, 2025

SilverArc Capital Management, LLC

2.02M

4.37%

+641.32K

+46.43%

Jun 30, 2025

Pontifax Venture Capital

1.49M

3.21%

-1.00

-0.00%

Mar 14, 2024

UBS Asset Management Switzerland AG

1.32M

2.85%

Jan 31, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Israel Innovative Technology ETF

2.09%

Tema Oncology ETF

1.92%

ALPS Medical Breakthroughs ETF

0.39%

Hypatia Women CEO ETF

0.28%

ProShares Ultra Nasdaq Biotechnology

0.16%

iShares Micro-Cap ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.07%

ARK Israel Innovative Technology ETF

占比2.09%

Tema Oncology ETF

占比1.92%

ALPS Medical Breakthroughs ETF

占比0.39%

Hypatia Women CEO ETF

占比0.28%

ProShares Ultra Nasdaq Biotechnology

占比0.16%

iShares Micro-Cap ETF

占比0.15%

Fidelity Enhanced Small Cap ETF

占比0.11%

Vanguard US Momentum Factor ETF

占比0.1%

Invesco Nasdaq Biotechnology ETF

占比0.09%

iShares Biotechnology ETF

占比0.07%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Urogen Pharma Ltd的前五大股东是谁？



Urogen Pharma Ltd 的前五大股东如下：
RTW Investments L.P.持有股份：4.54M，占总股份比例：9.82%。
Paradigm BioCapital Advisors LP持有股份：2.33M，占总股份比例：5.04%。
TD Securities, Inc.持有股份：3.19M，占总股份比例：6.90%。
Morgan Stanley & Co. LLC持有股份：1.47M，占总股份比例：3.19%。
Jefferies LLC持有股份：2.20M，占总股份比例：4.75%。